Next |
home / stock / ifrx / ifrx message board
Subject | By | Source | When |
---|---|---|---|
Closing of offering, here comes first stop $6.25 | Gator44 | investorshub | 04/18/2023 2:25:38 PM |
$IFRX should go slowly 5$ + | frans | investorshub | 04/17/2023 6:53:22 PM |
$IFRX 4.2 now slowly on the move | frans | investorshub | 04/17/2023 4:47:27 PM |
in here at 4.10 | frans | investorshub | 04/17/2023 4:30:35 PM |
Still in downtrend and they will keep diluting | the_stockoracle | investorshub | 04/13/2023 4:10:45 PM |
I bought more 4.04 | enthalpy | investorshub | 04/13/2023 2:13:43 PM |
Couple of pennies are cloce enough | Gator44 | investorshub | 04/13/2023 1:14:49 PM |
Learn your charts lol $3.93 is the gap fill | the_stockoracle | investorshub | 04/13/2023 1:11:39 PM |
Gap filled boys and girls... Big boy buying today !!! | Gator44 | investorshub | 04/13/2023 1:03:33 PM |
dont think we will see 3.50s but it | peterus | investorshub | 04/13/2023 6:36:07 AM |
Whats your thoughts on it hitting 3.50? | enthalpy | investorshub | 04/13/2023 12:25:12 AM |
When it hits $3.93 tomorrow is where Ill | the_stockoracle | investorshub | 04/12/2023 5:13:41 PM |
Tomorrow we probably hit 3.75ish and that's close | enthalpy | investorshub | 04/12/2023 3:37:46 PM |
Probably right. I loaded some at 4.20 with | enthalpy | investorshub | 04/12/2023 3:35:25 PM |
beter on side line and buy bottom | peterus | investorshub | 04/12/2023 3:25:36 PM |
it wil but not today | peterus | investorshub | 04/12/2023 2:59:42 PM |
I thought you said going to $10 lol | the_stockoracle | investorshub | 04/12/2023 2:53:12 PM |
im still on side line | peterus | investorshub | 04/12/2023 2:38:10 PM |
I disagree Im going to be buying at | the_stockoracle | investorshub | 04/12/2023 2:35:45 PM |
4.40s 4.50s could be stronge support | peterus | investorshub | 04/12/2023 1:25:57 PM |
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...